FAXSHEET

Date: Feb-10-2020 10:22:13

To: ORMC Infusion

Subject: Patient Document

Fax Number: 845-333-9400

To Company:

From Name: Armida, Ciera

From Company: HMG Goshen GI-70 Hatfield From Facility: HMG Goshen GI-70 Hatfield

Support Contact: 845-291-1260

Number of Page(s): 2

This facsimile transmission contains confidential information intended for the parties identified above. If you have received this transmission in error, please immediately notify me by telephone and return the original message to me at the address listed above. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.

	Con A LYME
£ (ORANGE
10,1	REGIONAL

CHEMOTHERAPY

Kelly	McManr
	Patient Label

MEDICAL CINTS	Ň.		- 7114	/ Lul 100			50H	
TO BE COMPLETE	DBY PHYS	ICIAN:	·	Patient	Name: K. McK		DOB: //Q/	184
Date Written: 1/20/20				Date of Administration: 215				
Diagnosis: Chon		:		TNM Stage:	1	All_	rgies: 🗹	VKDA
Protocol / Regimen	1-	*	And the second section of the second section of the second section second section section second second second		01	/ HILLS	i2Gaesens €‴ia	**************************************
Remicade	, 5m	· · ·	W	Cycle Day				
Venous Access:	Peripher		entral					
Height	Welght	Actual Ideal		Body Surface Area (m²)	Emetic Levi	3		
tt 🗀 in	56 kg	Adjust		wine (in)	Moders High	,		
Lab Orders:	CBC/DIFF		MP 🗆	Magnesium [UA	to the MANAGER TO A STREET A A STREET, ASSESSED.	#####	
Hold Parameters:								·
ANC less than:	WBC lea	e then:	PLT les	s than: Ho	b/lict less than:		er greater t	And the second s
Non-chemotherap	y orders:		Market San Committee and Market San Committee and Committe			RP	h initials/N	lurae înitiala
IV Fluids: N	S @ KVO (2	o mL/rir)	*		and the state of t			
		:					Milledon configuração de maior de escuentiva especia especia especia de espec	······································
	· · · · · · · · · · · · · · · · · · ·	3						
		<u> </u>	······································	Marie de la companya				

		 		······································				
			ŊijŶĸĸĸĸĸĸĸĸĸĸĸ ĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ					
				Abble Shill shift of the frame and the same				
Solution, volume a	ınd infusion I Məd down M	ate are per	r manufactui	rer/hospital guide	lines unless other	wise sper	oified. Chem	otherapeutic
the nearest vi	al size if with	in 10% of	calculated d	ose. Please adm	inister chemother	apy in sec	uence liste	below.
		se per	Dose		Dose			RPh/
Chemotherapy	,	Unit kg AUC)	Reduction (mg/m², mg/kg, AU	Dose	(Rounding to be completed by RPh)	Route	Infusion Rate	Nurse initiale
Remicade	5m	or Ica		280m	0	1		
,			- Anna Anna Anna Anna Anna Anna Anna Ann		1			
	- 					***************************************		de de la constitución de la cons
		÷			And the second s		***	
			65					
*If using a dose re	sduction, ni	eese drow	de rationel	111	11/	<u> </u>	<u> </u>	^.
MD Name (Print)	De CII.Y) J	MD 9lm	natura 1X	V/12	Det-Mi	_ Ilaa	lan
RN Name (Brint)	Ciorn	14	DN SIA	Mirro	1 / Pa		100	750
MD Name (Print) RN Name (Print) RPh Name (Print)			904 M.	I SERVICE CONTRACTOR			me Tlan	/
RPh Name (Print)		, , , , , , , , , , , , , , , , , , , 	nrn əigi	NACUTE		_Dete/Ti	me	
6.7			.					
Physi	olan Orders/Bla	nk/Chemothe		ME	20			